Reserve your spot for NHF 2016 Pre-conference Symposium on Specialty Pharmacy and Managed Care’s Role in Comprehensive Care on July 21.
Early clinical trial results in patients with hemophilia A show increased clotting factor levels in all subjects.
Patients with previous hepatitis B infection, cirrhosis or hepatocellular carcinoma need follow-up after treatment with direct-acting antivirals.
Scientists from the Indiana HTC and MicroHealth present the results of a 12-month study on the effect of HTC digital monitoring on annual bleeding rates.
NHF's Medical and Scientific Advisory Council (MASAC) issued the following three new documents, which were adopted by NHF’s Board of Directors on February 28, 2016.
YOU and EVERYONE ELSE in the bleeding disorders community are the reason why we reached an audience of 65 million with the Red Tie Challenge during Bleeding Disorders Awareness Month!
The American Journal of Hematology highlights the careers of female physicians who are movers and shakers in the community.
Despite advancements in therapies, men with severe hemophilia still experience debilitating joint bleeds, lowering their quality of life.
New recombinant factor VIII therapy is expected to reduce the number of weekly prophylactic infusions for those with hemophilia A.
Inspirational account of overcoming great obstacles concludes by urging everyone to take the Red Tie Challenge during Bleeding Disorders Awareness Month.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car